Proteomics in pathology, research and practice

Pathology Research and Practice

Volumn 200, Issue 2, 2004, Pages 69-82

  Röcken, Christoph ^a   Ebert, Matthias P A ^a   Roessner, Albert ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DNA; GENE PRODUCT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; ONCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEOME; TUMOR MARKER; VITAMIN D BINDING PROTEIN;

BIOCHEMISTRY; BIOINFORMATICS; BLADDER CANCER; BLOOD ANALYSIS; BREAST CANCER; CANCER RESEARCH; CANCER STAGING; CLINICAL PRACTICE; COLON CANCER; DISEASE MARKER; DNA FINGERPRINTING; EARLY DIAGNOSIS; GENETIC POLYMORPHISM; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LUNG CANCER; MAJOR HISTOCOMPATIBILITY COMPLEX; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEDICAL GENETICS; MEDICAL RESEARCH; OVARY CANCER; PANCREAS CANCER; PANCREAS JUICE; PATHOLOGY; PEPTIDE ANALYSIS; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN TARGETING; PROTEOMICS; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; TIME; TISSUE HOMOGENATE; TWO DIMENSIONAL ELECTROPHORESIS; URINALYSIS;

EID: 3242669995     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prp.2004.03.002     Document Type: Article

References (63)

1. Adam B.L. Qu Y. Davis J.W. Ward M.D. Clements M.A. Cazares L.H. Semmes O.J. Schellhammer P.F. Yasui Y. Feng Z. Wright G.L. Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men, Cancer Res. 62 2002 3609-3614
2. Admon A. Barnea E. Ziv T. Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides, Mol. Cell Proteomics 2 2003 388-398
3. Anderson N.G. Matheson A. Anderson N.L. Back to the future: The human protein index (HPI) and the agenda for post-proteomic biology, Proteomics 1 2001 3-12
4. Anderson N.L. Anderson N.G. The human plasma proteome: History, character, and diagnostic prospects, Mol. Cell Proteomics 1 2002 845-867
5. N.L. Anderson, M. Polanski, R. Pieper, T. Gatlin, R.S. Tirumalai, T.P. Conrads, T.D. Veenstra, J.N. Adkins, J.G. Pounds, R. Fagan, A. Lobley, The human plasma proteome: A non-redundant list developed by combination of four separate sources, Mol. Cell Proteomics (2004) January 12 (Epub ahead of print)
6. Baak J.P. Path F.R. Hermsen M.A. Meijer G. Schmidt J. Janssen E.A. Genomics and proteomics in cancer, Eur. J. Cancer 39 2003 1199-1215
7. Banez L.L. Prasanna P. Sun L. Ali A. Zou Z. Adam B.L. McLeod D.G. Moul J.W. Srivastava S. Diagnostic potential of serum proteomic patterns in prostate cancer, J. Urol. 170 2003 442-446
8. Bukowska A. Lendeckel U. Kähne T. Goette A. Proteomics in myocardial diseases, Pathol. Res. Pract. 200 2004 135-145
9. Cazares L.H. Adam B.L. Ward M.D. Nasim S. Schellhammer P.F. Semmes O.J. Wright G.L. Jr. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry, Clin. Cancer Res. 8 2002 2541-2552
10. Clarke W. Zhang Z. Chan D.W. The application of clinical proteomics to cancer and other diseases, Clin. Chem. Lab. Med. 41 2003 1562-1570
11. Coombes K.R. Fritsche H.A. Jr. Clarke C. Chen J.N. Baggerly K.A. Morris J.S. Xiao L.C. Hung M.C. Kuerer H.M., Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization, Clin. Chem. 49 2003 1615-1623
12. Diamandis E.P. Point: Proteomic patterns in biological fluids: Do they represent the future of cancer diagnostics? Clin. Chem. 49 2003 1272-1275
13. Diamandis E.P. Serum proteomic patterns for detection of prostate cancer, J. Natl. Cancer Inst. 95 2003 489-490
14. Drynda S. Ringel B. Kekow M. Kühne C. Drynda A. Glocker M.O. Thiesen H.J. Kekow J. Proteome analysis reveals disease-associated marker proteins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti-TNFa therapy Pathol. Res. Pract. 200 2004 165-171
15. Espina V. Dettloff K.A. Cowherd S. Petricoin E.F. Liotta L.A. Use of proteomic analysis to monitor responses to biological therapies, Expert Opin. Biol. Ther. 4 2004 83-93
16. Hirano T. Manabe T. Takeuchi S. Serum cathepsin B levels and urinary excretion of cathepsin B in the cancer patients with remote metastasis, Cancer Lett. 70 1993 41-44
17. Hlavaty J.J. Partin A.W. Kusinitz F. Shue M.J. Stieg A. Bennett K. Briggman J.V. Mass spetrometry as a discovery tool for identifying serum markers for prostate cancer, Clin. Chem. 47 2001 1924-1926
18. Hlavaty J.J. Partin A.W. Shue M.J. Mangold L.A. Derby J. Javier T. Kelley S. Stieg A. Briggman J.V. Hass G.M. Wu Y.J. Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer, Urology 61 2003 1261-1265
19. Kellner U. Steiner S. Seibert V. Heim S. Kellner A. Schulz H.U. Krüger S. Roessner A. Reymond M., Epithelial cell preparation for proteomic and transcriptomic analysis in human pancreatic tissue, Pathol. Res. Pract. 200 2004 155-163
20. Koblinski J.E. Ahram M. Sloane B.F. Unraveling the role of proteases in cancer, Clin. Chim. Acta. 291 2000 113-135
21. Koopmann J. Zhang Z. White N. Rosenzweig J. Fedarko N. Jagannath S. Canto M.I. Yeo C.J. Chan D.W. Goggins M. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry, Clin. Cancer Res. 10 2004 860-868
22. Kos J. Nielsen H.J. Krasovec M. Christensen I.J. Cimerman N. Stephens R.W. Brunner N., Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer, Clin. Cancer Res. 4 1998 1511-1516
23. Kozak K.R. Amneus M.W. Pusey S.M. Su F. Luong M.N. Luong S.A. Reddy S.T. Farias-Eisner R. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis, Proc. Natl. Acad. Sci. USA 100 2003 12343-12348
24. Lage H. Proteomics in cancer cell research: An analysis of therapy resistance, Pathol. Res. Pract. 200 2004 105-117
25. Lander E.S. Linton L.M. Birren B. et al. Initial sequencing and analysis of the human genome, Nature 409 2001 860-921
26. Lehrer S. Roboz J. Ding H. Zhao S. Diamond E.J. Holland J.F. Stone N.N. Droller M.J. Stock R.G. Putative protein markers in the sera of men with prostatic neoplasms, BJU Int. 92 2003 223-225
27. Lewczuk P. Esselmann H. Meyer M. Wollscheid V. Neumann M. Otto M. Maler J.M. Ruther E. Kornhuber J. Wiltfang J. The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: Evidence of a novel carboxyterminally elongated abeta peptide, Rapid Commun. Mass Spectrom. 17 2003 1291-1296
28. Li J. Zhang Z. Rosenzweig J. Wang Y.Y. Chan D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer, Clin. Chem. 48 2002 1296-1304
29. Makarewicz R. Drewa G. Szymanski W. Skonieczna-Makarewicz I., Cathepsin B in predicting the extent of the cervix carcinoma, Neoplasma 42 1995 21-24
30. Nishizuka S. Chen S.T. Gwadry F.G. Alexander J. Major S.M. Scherf U. Reinhold W.C. Waltham M. Charboneau L. Young L. Bussey K.J. Kim S. Lababidi S. Lee J.K. Pittaluga S. Scudiero D.A. Sausville E.A. Munson P.J. Petricoin E.F. III Liotta L.A. Hewitt S.M. Raffeld M. Weinstein J.N. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: Identification by genomic, proteomic, and tissue array profiling, Cancer Res. 63 2003 5243-5250
31. Paweletz C.P. Gillespie J. Ornstein D.K. Simone N.L. Brown M.R. Cole K.A. Wang Q.H. Huang J. Hu N. Yip T.T. Rich W.E. Kohn E.C. Linehan W.M. Weber T. Taylor P. Emmert-Buck M. Liotta L. Petricoin E.F. III Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip, Drug Dev. Res. 49 2000 34-42
32. Paweletz C.P. Trock B. Pennanen M. Tsangaris T. Magnant C. Liotta L.A. Petricoin E.F. III Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: Potential for new biomarkers to aid in the diagnosis of breast cancer, Dis. Markers 17 2001 301-307
33. Petricoin E.F. Ardekani A.M. Hitt B.A. Levine P.J. Fusaro V.A. Steinberg S.M. Mills G.B. Simone C. Fishman D.A. Kohn E.C. Liotta L.A. Use of proteomic patterns in serum to identify ovarian cancer, Lancet 359 2002 572-577
34. Petricoin E.F. Liotta L.A. Clinical applications of proteomics, J. Nutr. 133 2003 2476S-2484S
35. Petricoin E.F. III Ornstein D.K. Paweletz C.P. Ardekani A. Hackett P.S. Hitt B.A. Velassco A. Trucco C. Wiegand L. Wood K. Simone C.B. Levine P.J. Linehan W.M. Emmert-Buck M.R. Steinberg S.M. Kohn E.C. Liotta L.A., Serum proteomic patterns for detection of prostate cancer, J. Natl. Cancer Inst. 94 2002 1576-1578
36. Pieper R. Gatlin C.L. Makusky A.J. Russo P.S. Schatz C.R. Miller S.S. Su Q. McGrath A.M. Estock M.A. Parmar P.P. Zhao M. Huang S.T. Zhou J. Wang F. Esquer-Blasco R. Anderson N.L. Taylor J. Steiner S. The human serum proteome: Display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins, Proteomics 3 2003 1345-1364
37. Porta M. Fernandez E. Alguacil J. Semiology, proteomics, and the early detection of symptomatic cancer, J. Clin. Epidemiol. 56 2003 815-819
38. Powell K. Proteomics delivers on promise of cancer biomarkers, Nat. Med. 9 2003 980
39. Qu Y. Adam B.L. Yasui Y. Ward M.D. Cazares L.H. Schellhammer P.F. Feng Z. Semmes O.J. Wright G.L. Jr. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients, Clin. Chem. 48 2002 1835-1843
40. Reymond M.A. Steinert R. Kähne T. Sagynaliev E. Allal A.S. Lippert H. Expression and functional proteomics studies in colorectal cancer, Pathol. Res. Pract. 200 2004 119-127
41. Rogers M.A. Clarke P. Noble J. Munro N.P. Paul A. Selby P.J. Banks R.E., Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: Identification of key issues affecting potential clinical utility, Cancer Res. 63 2003 6971-6983
42. Rosenblatt K.P. Bryant-Greenwood P. Killian J.K. Mehta A. Geho D. Espina V. Petricoin E.F. Liotta L.A. Serum proteomics in cancer diagnosis and management, Annu. Rev. Med. 55 2004 97-112
43. Rosty C. Christa L. Kuzdzal S. Baldwin W.M. Zahurak M.L. Carnot F. Chan D.W. Canto M. Lillemoe K.D. Cameron J.L. Yeo C.J. Hruban R.H. Goggins M. Identification of hepatocarcinoma-intestine-pancreas/ pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology, Cancer Res. 62 2002 1868-1875
44. Sauter E.R. Zhu W. Fan X.J. Wassell R.P. Chervoneva I. Du Bois G.C. Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer, Br. J. Cancer 86 2002 1440-1443
45. Seibert V. Wiesner A. Buschmann T. Meuer J. Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI TOF-MS) and ProteinChip technology in proteomics research, Pathol. Res. Pract. 200 2004 83-94
46. P. Stattin, M. Hakama, Correspondence re: B.-L. Adam et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men, Cancer Res. 63 (2003) 2701-2702
47. P. Stattin, M. Hakama, Correspondence re: B.-L. Adam, et al., Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 63 (2003) 2701-2702.
48. F.M. Tumminello, G. Leto, G. Pizzolanti, V. Candiloro, M. Crescimanno, L. Crosta, C. Flandina, G. Montalto, M. Soresi, A. Carroccio, F. Bascone, I. Ruggeri, S. Ippolito, N. Gebbia, Cathepsin D, B and L circulating levels as prognostic markers of malignant progression, Anticancer Res. 16 (1996) 2315-2319
49. Venter J.C. Adams M.D. Myers E.W. et al. The sequence of the human genome, Science 291 2001 1304-1351
50. Verma M. Kagan J. Sidransky D. Srivastava S., Proteomic analysis of cancer-cell mitochondria, Nat. Rev. Cancer 3 2003 789-795
51. Vlahou A. Schellhammer P.F. Mendrinos S. Patel K. Kondylis F.I. Gong L. Nasim S. Wright J.G. Jr. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine, Am. J. Pathol. 158 2001 1491-1502
52. Wadsworth J.T. Somers K.D. Stack B.C.Jr. Cazares L. Malik G. Adam B.L. Wright G.L. Jr. Semmes O.J. Identification of patients with head and neck cancer using serum protein profiles, Arch. Otolaryngol. Head Neck Surg. 130 2004 98-104
53. Waldburg N. Kähne T. Reisenauer A. Röcken C. Welte T. Bühling F., Clinical proteomics in lung diseases, Pathol. Res. Pract. 200 2004 147-154
54. Warwas M. Haczynska H. Gerber J. Nowak M. Cathepsin B-like activity as a serum tumour marker in ovarian carcinoma, Eur. J. Clin. Chem. Clin. Biochem. 35 1997 301-304
55. Wellmann A. Wollscheid V. Lu H. Ma Z.L. Albers P. Schutze K. Rohde V. Behrens P. Dreschers S. Ko Y. Wernert N. Analysis of microdissected prostate tissue with ProteinChip arrays - a way to new insights into carcinogenesis and to diagnostic tools, Int. J. Mol. Med. 9 2002 341-347
56. Wright G.L. Jr. Cazares L.H. Leung S.M. Nasim S. Adam B.L. Yip T.T. Schellhammer P.F. Gong L. Vlahou A., Proteinchip(R) surface enhanced laser desorption/ionization (SELDI) mass spectrometry: A novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures, Prostate Cancer Prostatic Dis. 2 1999 264-276
57. Wulfkuhle J.D. Liotta L.A. Petricoin E.F. Proteomic applications for the early detection of cancer, Nat. Rev. Cancer 3 2003 267-275
58. Xiao X. Liu D. Tang Y. Guo F. Xia L. Liu J. He D. Development of proteomic patterns for detecting lung cancer, Dis. Markers 19 2003 33-39
59. Xiao Z. Adam B.L. Cazares L.H. Clements M.A. Davis J.W. Schellhammer P.F. Dalmasso E.A. Wright G.L. Jr. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease, Cancer Res. 61 2001 6029-6033
60. Ye B. Cramer D.W. Skates S.J. Gygi S.P. Pratomo V. Fu L. Horick N.K. Licklider L.J. Schorge J.O. Berkowitz R.S. Mok S.C. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry, Clin. Cancer Res. 9 2003 2904-2911
61. Zheng Y. Xu Y. Ye B. Lei J. Weinstein M.H. O'Leary M.P. Richie J.P. Mok S.C. Liu B.C., Prostate carcinoma tissue proteomics for biomarker discovery, Cancer 98 2003 2576-2582
62. Zhukov T.A. Johanson R.A. Cantor A.B. Clark R.A. Tockman M.S. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry, Lung Cancer 40 2003 267-279
63. Zore I. Krasovec M. Cimerman N. Kuhelj R. Werle B. Nielsen H.J. Brunner N. Kos J. Cathepsin B/cystatin C complex levels in sera from patients with lung and colorectal cancer, Biol. Chem. 382 2001 805-810